![A selective ERK5 inhibitor (IC50 = 0.162 µM in an enzyme assay); selective for ERK5 over a panel of more than 200 kinases at 10 µM; inhibits ERK5 phosphorylation (IC50 = 0.09 µM in HeLa cells); decreases AP-1 transcriptional activity (EC50 = 4.2 µM); inhibits human recombinant LRRK2[G2019S] (IC50 = 0.339 µM in an enzyme assay)](https://interpriseusa.com/wp-content/uploads/2021/06/25448.png)
Description
A selective ERK5 inhibitor (IC50 = 0.162 µM in an enzyme assay); selective for ERK5 over a panel of more than 200 kinases at 10 µM; inhibits ERK5 phosphorylation (IC50 = 0.09 µM in HeLa cells); decreases AP-1 transcriptional activity (EC50 = 4.2 µM); inhibits human recombinant LRRK2[G2019S] (IC50 = 0.339 µM in an enzyme assay)
Formal name: 11-cyclopentyl-2-[[2-ethoxy-4-[[4-(4-methyl-1-piperazinyl)-1-piperidinyl]carbonyl]phenyl]amino]-5,11-dihydro-5-methyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
Synonyms: ERK5-IN-1
Molecular weight: 638.8
CAS: 1435488-37-1
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Kinase Inhibitors|Other Serine/Threonine Kinases||Product Type|Biochemicals|Kinase Inhibitors|RAS/RAF/MEK/ERK/MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease
